logo
Plus   Neg
Share
Email

Novartis : EU Approves Mayzent For Treatment Of Adult Patients With SPMS

Novartis (NVS) said that the European Commission has approved Mayzent or siponimod for the treatment of adult patients with secondary progressive multiple sclerosis or SPMS with active disease evidenced by relapses or imaging features of inflammatory activity.

The company noted that Mayzent addresses an unmet need for SPMS patients with active disease who, until now, did not have an oral treatment that has been shown to be effective in delaying progression in this patient population.

Multiple Sclerosis or MS disrupts the normal functioning of the brain, optic nerves and spinal cord through inflammation and tissue loss.

Multiple Sclerosis, which affects about 2.3 million people worldwide, is often characterized into three forms: primary progressive MS (PPMS), relapsing-remitting MS (RRMS), and SPMS, which follows from an initial RRMS course and is characterized by physical and cognitive changes over time, in presence or absence of relapses, leading to a progressive accumulation of neurological disability.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Global PC shipments returned to growth in the second quarter of 2020 after seeing a significant decline in the preceding first quarter due to COVID-19 related supply-chain disruptions, according to reports by two research firms. The PC market returned to growth in the quarter as production ramped up and vendors restocked their supplies to near-normal levels. The bankruptcy filing of America's oldest apparel retailer Brooks Brothers has ignited significant interest from potential buyers for the brand. WHP Global and a venture backed by Authentic Brands Group LLC and Simon Property Group, Inc., are reportedly considering bids for the retailer. WHP Global owns the ANNE KLEIN and JOSEPH ABBOUD brands. Sundial Herbal Products has recalled around 65 products, which were misbranded and currently unapproved drugs, the U.S. Food and Drug Administration said in a statement. The recall follows an order by a federal judge in June to stop distributing the company's unapproved new drugs. The affected items include herbal products and dietary supplements.
Follow RTT